All News

The FDA issues warning letters to 3 infant formula manufacturers for violations, and officials with the Department of Health and Human Services recommend reclassifying marijuana as a schedule III drug.

Sometimes, breaches in information are the result of a simple mistake. How can those be avoided?

Narcan is set to be available at several drugstore and grocery chains in the US early next week, and Walmart announced a new "Testing and Treatment" program at its pharmacies in 12 states.

CMS announces the first 10 drugs selected for price negotiation under Medicare Part D, and a new study finds prescriptions for fruits and vegetables can improve health outcomes for people at increased risk of cardiovascular disease.

Your weekly roundup of the latest news from Drug Topics®.

The new deadline to be in compliance with the requirements will be November 27, 2024.

Sandoz's injection treatment natalizumab-sztn (Tyruko) is the first biosimilar approved by the health agency for the treatment of multiple sclerosis.

HHS awards money for mental health awareness training, UnitedHealthcare pays $80,000 over potential HIPPA violation, and the FDA issues a recall for sub-acute care ventilators.

CVS Health joins the biosimilar market, the FDA issues warning about contaminated eye drops, and the CDC says not to kiss your pet turtle because of salmonella.

One in 5 women report mistreatment during maternity care, employers see rise in mental health challenges, and Microsoft teams up with Epic to increase the use of AI in healthcare.

Poll finds Americans still struggle with health misinformation, CMS release new guidance on out-of-pocket Prescription Drug Cost Program, and experts call for continued masking in health care settings.

NIH establishes research centers for maternal health, FDA grants priority review for IgA nephropathy treatment, and the CDC begins tracking a new COVID-19 variant.

Appeals court puts restrictions on access to mifepristone, Blue Shield of California drops CVS Health, and Americans think opioids and obesity are the 2 biggest threats to public health.

National organizations call for Improvements to youth mental health care, Wednesday marks 1 year since passing of Inflation Reduction Act, and a new study finds link between fracking and lymphoma.

In the pharmacy field, customers are not often knowledgeable about the specifics of the products they are purchasing. How can your pharmacy make sure customers get exactly what they need?

Philips recall declared class I by the FDA, HHS launches civil rights investigation into Tennessee medical center, and experts warn about chemicals released into air and water during Maui wildfires.

The act is currently set to go into effect in just over three months.

Your weekly roundup of the latest news from Drug Topics®.

HHS awards money to fight the nursing shortage, the FDA approves Johnson & Johnson's talquetamab-tgvs (TALVEY), and the CDC says suicides reached an all-time high in 2022.

WHO upgrades EG.5 to "variant of interest," Amazon-owned One Medical expands across US, and health officials urge vaccination before the coming fall season.

COVID-19 hospitalizations tick up, Wegovy shows cardiovascular benefit, and health care organizations team up to fight overdose deaths in New Jersey.

What's on the agenda for FTP in the month to come?

Omicron EG.5 COVID-19 variant takes hold in the US, new inclusive blood donation guidance goes into effect, and the national uninsured rate reaches a new all-time low.

Drug Topics spoke with Peter Koo, PharmD, RPh at McKesson ideaShare 2023 about the launch of Foster & Thrive.

Hear the pharmacists from Eden Drug, Hazel Green, and Professional Pharmacy on their reactions to being a finalist for this award and more.

A Q&A with Marc Ost, co-owner of Eric’s RX Shoppe, which was one of the first community pharmacies to receive the new vaccine.

Afoxolaner, moxidectin, and pyrantel chewable tablets protect dogs from fleas, ticks, heartworm disease, roundworms, and hookworms.

Be sure to vote in this month's poll!

The risk of drug shortages is increasing as the long-term sustainability of generic manufacturing faces challenges, including low return on investment because of lowered prices, drug purchasers becoming more concentrated, and new generics facing slow adoption.

Quizartinib (Vanflyta) is an oral inhibitor of FLT3, and it specifically targets FLT3-ITD mutations, which drive cancer growth and contribute to increased risk of relapse and shorter overall survival.